Trial Profile
Phase 1, Non-comparative, Open-Label Study of Pharmacokinetics and Safety of a Single-Dose of ZTI-01 (Fosfomycin for Injection) in Pediatric Subjects (<12 Years of Age)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Fosfomycin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Acronyms Pediatric_PK
- Sponsors Nabriva Therapeutics; Zavante Therapeutics
- 14 Sep 2023 Planned End Date changed from 10 Jan 2023 to 10 Jan 2026.
- 14 Sep 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2025.
- 03 Mar 2022 Planned End Date changed from 10 Jan 2022 to 10 Jan 2023.